Intestinal transplantation is just now beginning to emerge as a viable therapeutic option for the large number of patients worldwide with intestinal failure. Intestinal transplantation has experienced consistent growth over the last decade as clinical outcomes have improved. As more centers gain experience in performing and managing these complex transplant patients, referral patterns are established to facilitate the movement of patients to those centers with expertise in this area. As these intestinal transplant centers evolve, indications for intestinal transplantation will change and more patients will be helped. It is critical that general surgeons and gastroenterologists are familiar with the field of intestinal transplantation, as many of their most difficult patients may derive great benefit from this option.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Oxygenation and intestinal perfusion and its association with perturbations of the early life gut microbiota composition of children with congenital heart disease.
Front Microbiol
January 2025
German Centre for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany.
Background: Early life gut microbiota is known to shape the immune system and has a crucial role in immune homeostasis. Only little is known about composition and dynamics of the intestinal microbiota in infants with congenital heart disease (CHD) and potential influencing factors.
Methods: We evaluated the intestinal microbial composition of neonates with CHD ( = 13) compared to healthy controls (HC, = 30).
The Pancreas: The Final Frontier.
Gastroenterol Clin North Am
March 2025
Intestinal Rehabilitation and Transplant Center, Department of Surgery/UI Health University of Illinois at Chicago, 840 South Wood Street, Suite 402 (MC958), Chicago, IL 60612, USA. Electronic address:
Impact of dairy calf management practices on the intestinal tract microbiome pre-weaning.
J Med Microbiol
January 2025
Animal and Agriculture Department, Hartpury University, Gloucester, GL19 3BE, UK.
Microbiota in the gastrointestinal tract (GIT) consisting of the rumen and hindgut (the small intestine, cecum and colon) in dairy calves play a vital role in their growth and development. This review discusses the development of dairy calf intestinal microbiomes with an emphasis on the impact that husbandry and rearing management have on microbiome development, health and growth of pre-weaned dairy calves. The diversity and composition of the microbes that colonize the lower GIT (small and large intestine) can have a significant impact on the growth and development of the calf, through influence on nutrient metabolism, immune modulation, resistance or susceptibility to infection, production outputs and behaviour modification in adult life.
View Article and Find Full Text PDFAbdominal LIPUS Stimulation Prevents Cognitive Decline in Hind Limb Unloaded Mice by Regulating Gut Microbiota.
Mol Neurobiol
January 2025
Center for Biomedical Engineering, School of Information Science and Technology, Fudan University, Shanghai, 200433, China.
Weightlessness usually causes disruption of the gut microbiota and impairs cognitive function. There is a close connection between gut microbiota and neurological diseases. Low-intensity pulsed ultrasound (LIPUS) has a beneficial effect on reducing intestinal inflammation.
View Article and Find Full Text PDFAtezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial.
ESMO Open
January 2025
Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, (Milan), Italy. Electronic address:
Background: The treatment of advanced hepatocellular carcinoma (HCC) with atezolizumab and bevacizumab led to significant improvements in overall survival (OS), progression-free survival (PFS), and response rate compared with sorafenib in the phase III IMbrave150 trial. The etiology of background liver disease can differ between Eastern and Western populations, leading to a potentially different impact of systemic therapies; therefore the unequal representation must be considered in the IMbrave150 trial. To provide further data on the safety and effectiveness of atezolizumab and bevacizumab, the phase IIIb AMETHISTA (Atezolizumab plus bevacizumab in METastatic HCC Italian Safety TriAl) ran in a Western (Italian) population of patients with advanced HCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!